期刊
CELL METABOLISM
卷 24, 期 1, 页码 15-30出版社
CELL PRESS
DOI: 10.1016/j.cmet.2016.06.009
关键词
-
资金
- Canada Research Chair in Regulatory Peptides
- Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology
- Arisaph Pharmaceuticals Inc.
- Intarcia Therapeutics
- Merck Research Laboratories
- MedImmune
- Novo Nordisk Inc.
- Receptos
- Sanofi, Inc.
- GSK
- Merck
- Novo Nordisk
- Sanofi Inc.
Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose metabolism and energy homeostasis through regulation of islet hormone secretion, gastrointestinal motility, and food intake, enabling development of GLP-1 receptor (GLP-1R) agonists for the treatment of diabetes and obesity. GLP-1 also acts on the immune system to suppress inflammation, and GLP-1R signaling in multiple tissues impacts cardiovascular function in health and disease. Here we review how GLP-1 and clinically approved GLP-1R agonists engage mechanisms that influence the risk of developing cardiovascular disease. We discuss how GLP-1R agonists modify inflammation, cardiovascular physiology, and pathophysiology in normal and diabetic animals through direct and indirect mechanisms and review human studies illustrating mechanisms linking GLP-1R signaling to modification of the cardiovascular complications of diabetes. The risks and benefits of GLP-1R agonists are updated in light of recent data suggesting that GLP-1R agonists favorably modify outcomes in diabetic subjects at high risk for cardiovascular events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据